Yang Q, Zhang H, Yu Y, et al. - As the incidence of carbapenem-resistant Enterobacteriaceae is increasing in China, researchers sought to demonstrate the in vitro effectiveness of imipenem/relebactam (IMI/REL) on clinical Enterobacteriaceae isolates retrieved from intra-abdominal infections (IAIs), respiratory tract infections (RTIs), and urinary tract infections (UTIs) in China between 2015 and 2018. From 22 hospitals across 7 geographic regions of China, they obtained 8,781 Enterobacteriaceae isolates from IAI, RTI, and UTI samples. Escherichia coli was identified to be the most frequently detected Enterobacteriaceae species (n = 4,676 [53.3%]), followed by Klebsiella pneumoniae (n = 2,949 [33.6%]) and Enterobacter cloacae (n = 542 [6.2%]). Observations revealed their high in vitro susceptibility. Hence, consideration should be given to Enterobacteriaceae infections in China for IMI/REL treatment, especially with isolates that are not susceptible to carbapenems.